 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon |
|
Diabetes Metab J. 2021;45(6):954-959. Published online November 12, 2020 DOI: https://doi.org/10.4093/dmj.2020.0173 |
|
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus Diabetes & Metabolism Journal. 2021;45(6):954-959  Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial The Lancet. 2019;394(10208):1519-1529 Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus Diabetes, Obesity and Metabolism. 2009;11(5):506-515 Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes Diabetes Therapy. 2020;11(11):2465-2476 Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus Korean Diabetes Journal. 2010;34(6):331 Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin‐metformin combination in newly diagnosed Type 2 diabetes Diabetic Medicine. 2019;36(4):505-513 1159-P: Metformin Monotherapy Changes Gut Microbiota in Newly Diagnosed Type 2 Diabetes Diabetes. 2019;68(Supplement_1): A strategy implementing initial therapy with a fixed- dose combination tablet of sitagliptin and metformin in patients with type 2 diabetes provides superior glycaemic control compared with a strategy using initial metformin monotherapy over 44 weeks Canadian Journal of Diabetes. 2009;33(3):208-209 Initial Combination with Linagliptin and Metformin in Newly Diagnosed Type 2 Diabetes and Severe Hyperglycemia Advances in Therapy. 2012;29(12):1005-1015 Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2012;125 |
